The heterogeneity of cellular states in cancer has been linked to drug resistance, cancer progression and the presence of cancer cells with properties of normal tissue stem cells. Secreted Wnt signals maintain stem cells in various epithelial tissues, including in lung development and regeneration. We believe that uncovering pathways controlling of stem-like cell and niche cell phenotypes in cancer can be leveraged to develop conceptually novel therapies for patients. Our group utilizes many molecular techniques, including the RNAscope technology, to elucidate the molecular mechanisms that determine the niche cell fate, which may prove to be useful therapeutic targets in cancer therapy.
In this webinar, we will show that mouse and human lung adenocarcinomas display hierarchical features with two distinct subpopulations, one with high Wnt signaling activity and another forming a niche that provides the Wnt ligand.
Traditional ISH users considering RNAscope ISH Current IHC users having antibody challenges Users performing ISH combined with IHC New and experienced RNAscope & BaseScope assay users.
In this webinar, you will learn how RNA in situ Hybridization (RNA ISH) and in particular the RNAscope ISH assay can be applied to deciphering the molecular mechanisms of targeted therapies for cancer and other disease states. You will learn how this technique may be easily adapted for many tissues or cell preparations, including FFPE, fresh-frozen, single cell assay preparations.
To watch the on-demand recorded webinar please click here
